Top

Published in:

01-12-2013 | Translational Research and Biomarkers

Expression of GOLM1 Correlates with Prognosis in Human Hepatocellular Carcinoma

Authors: Ming-Huang Chen, MD, PhD, Yi-Hua Jan, PhD, Peter Mu-Hsin Chang, MD, PhD, Yung-Jen Chuang, PhD, Yi-Chen Yeh, MD, Hao-Jan Lei, PhD, Michael Hsiao, PhD, Shiu-Feng Huang, PhD, Chi-Ying F. Huang, PhD, Gar-Yang Chau, MD, PhD

Published in: Annals of Surgical Oncology | Special Issue 3/2013

Abstract

Background

Serum Golgi membrane protein 1 (GOLM1) is a novel biomarker for hepatocellular carcinoma (HCC). However, few studies have investigated the relationship between GOLM1 protein expression and clinicopathologic features in HCC patients. The aim of this study was to investigate the expression of GOLM1 in human HCC and its correlation with clinicopathologic parameters.

Methods

Clinicopathologic data were obtained through a detailed retrospective review of the medical records of 193 patients with HCC who had undergone surgical resection between 1990 and 2006 at the Taipei Veterans General Hospital. Another 120 HCC tissue samples provided by the Taiwan Liver Cancer Network were used as validation cohort. Immunohistochemical staining was used to determine the expression of GOLM1 in archived formalin-fixed, paraffin-embedded tissue specimens.

Results

GOLM1 expression was significantly higher in resected HCC tumor tissues than in corresponding normal liver tissues (p < 0.01). After a median follow-up of 51 months, multivariate analysis showed that portal vein invasion (hazard ratio [HR], 1.515; 95 % confidence interval [95 % CI], 1.008–2.277; p = 0.046) and high GOLM1 protein expression (HR, 1.696; 95 % CI, 1.160–2.479; p = 0.006) were independent prognostic factors for poor overall survival. High GOLM1 protein expression still significantly correlates with worse overall survival as well as disease-free survival in the validation cohort (p < 0.001 and p = 0.002).

Conclusions

Overexpression of GOLM1 is associated with poor prognosis in human HCC.

El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127.PubMedCrossRef

El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–1763.PubMedCrossRef

Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10:204–209.PubMedCrossRef

Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236.PubMedCrossRef

Wong LL, Limm WM, Severino R, Wong LM. Improved survival with screening for hepatocellular carcinoma. Liver Transpl. 2000;6:320–325.PubMedCrossRef

Min YW, Gwak GY, Lee MW, Choi MS, Lee JH, Koh KC, et al. Clinical course of sub-centimeter-sized nodules detected during surveillance for hepatocellular carcinoma. World J Gastroenterol. 2012;18:2654–2660.PubMedCrossRef

Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012;21:793–799.PubMedCrossRef

Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994;19:61–66.PubMedCrossRef

Giannelli G, Antonaci S. New frontiers in biomarkers for hepatocellular carcinoma. Dig Liver Dis. 2006;38:854–859.PubMedCrossRef

10.

Ozkan H, Erdal H, Tutkak H, Karaeren Z, Yakut M, Yüksel O, et al. Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma. Digestion. 2011;83:83–88.PubMedCrossRef

11.

Mao Y, Yang H, Xu H, Lu X, Sang X, Du S, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 2010;59:1687–1693.PubMedCrossRef

12.

Li X, Wu K, Fan D. Serum Golgi Phosphoprotein two level: a better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma. Hepatology. 2009;50:325.PubMedCrossRef

13.

Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, et al. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene. 2000;249:53–65.PubMedCrossRef

14.

Zhou Y, Li L, Hu L, Peng T. Golgi phosphoprotein 2 (GOLPH2/GP73/GOLM1) interacts with secretory clusterin. Mol Biol Rep. 2011;38:1457–1462.PubMedCrossRef

15.

Hu L, Li L, Xie H, Gu Y, Peng T. The Golgi localization of GOLPH2 (GP73/GOLM1) is determined by the transmembrane and cytoplasmic sequences. PloS One. 2011;6:e28207.PubMedCrossRef

16.

Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology. 2007;45:938–947.PubMedCrossRef

17.

Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 2001;23:291–299.PubMed

18.

Chen MH, Yeh YC, Shyr YM, Jan YH, Chao Y, Li CP, et al. Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors. J Gastroenterol. 2013;48:101–108.PubMedCrossRef

19.

Riener MO, Stenner F, Liewen H, Soll C, Breitenstein S, Pestalozzi BC, et al. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology. 2009;49:1602–1609.PubMedCrossRef

20.

Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology. 2002;35:1431–1440.PubMedCrossRef

21.

Sun Y, Yang H, Mao Y, Xu H, Zhang J, Li G, et al. Increased Golgi protein 73 expression in hepatocellular carcinoma tissue correlates with tumor aggression but not survival. J Gastroenterol Hepatol. 2011;26:1207–1212.PubMedCrossRef

22.

Ando E, Kuromatsu R, Tanaka M, Takada A, Fukushima N, Sumie S, et al. Surveillance program for early detection of hepatocellular carcinoma in Japan: results of specialized department of liver disease. J Clin Gastroenterol. 2006;40:942–948.PubMedCrossRef

23.

Shim JH, Yoon DL, Han S, Lee YJ, Lee SG, Kim KM, et al. Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis. Ann Surg Oncol. 2012;19:3687–3696.PubMedCrossRef

Title: Expression of GOLM1 Correlates with Prognosis in Human Hepatocellular Carcinoma
Authors: Ming-Huang Chen, MD, PhD
Yi-Hua Jan, PhD
Peter Mu-Hsin Chang, MD, PhD
Yung-Jen Chuang, PhD
Yi-Chen Yeh, MD
Hao-Jan Lei, PhD
Michael Hsiao, PhD
Shiu-Feng Huang, PhD
Chi-Ying F. Huang, PhD
Gar-Yang Chau, MD, PhD
Publication date: 01-12-2013
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue Special Issue 3/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-013-3101-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Expression of GOLM1 Correlates with Prognosis in Human Hepatocellular Carcinoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Special Issue 3/2013

Erratum to: Up-front Hepatic Resection for Metastatic Colorectal Cancer Results in Favorable Long-term Survival

Increased BCAR1 Predicts Poor Outcomes of Non-small Cell Lung Cancer in Multiple-Center Patients

Overexpression of Membrane Proteins in Primary and Metastatic Gastrointestinal Neuroendocrine Tumors

Hypermethylation of HIC1 Promoter and Aberrant Expression of HIC1/SIRT1 Might Contribute to the Carcinogenesis of Pancreatic Cancer

Erratum to: High Expression of Sonic Hedgehog Signaling Proteins Is Related to the Favorable Outcome, EGFR Mutation, and Lepidic Predominant Subtype in Primary Lung Adenocarcinoma

Erratum to: Influence of Comorbidity and Age on 1-, 2-, and 3-Month Postoperative Mortality Rates in Gastrointestinal Cancer Patients